These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

275 related articles for article (PubMed ID: 26652296)

  • 1. Intracellular and extracellular microtubule associated protein tau as a therapeutic target in Alzheimer disease and other tauopathies.
    Avila J; Pallas N; Bolós M; Sayas CL; Hernandez F
    Expert Opin Ther Targets; 2016 Jun; 20(6):653-61. PubMed ID: 26652296
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Tau-based therapies in neurodegeneration: opportunities and challenges.
    Li C; Götz J
    Nat Rev Drug Discov; 2017 Dec; 16(12):863-883. PubMed ID: 28983098
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Novel drugs affecting tau behavior in the treatment of Alzheimer's disease and tauopathies.
    Navarrete LP; Pérez P; Morales I; Maccioni RB
    Curr Alzheimer Res; 2011 Sep; 8(6):678-85. PubMed ID: 21605038
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Recent developments with tau-based drug discovery.
    Iqbal K; Liu F; Gong CX
    Expert Opin Drug Discov; 2018 May; 13(5):399-410. PubMed ID: 29493301
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Tau pathology in Alzheimer disease and other tauopathies.
    Iqbal K; Alonso Adel C; Chen S; Chohan MO; El-Akkad E; Gong CX; Khatoon S; Li B; Liu F; Rahman A; Tanimukai H; Grundke-Iqbal I
    Biochim Biophys Acta; 2005 Jan; 1739(2-3):198-210. PubMed ID: 15615638
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Alzheimer's disease: phenotypic approaches using disease models and the targeting of tau protein.
    Lauretti E; Praticò D
    Expert Opin Ther Targets; 2020 Apr; 24(4):319-330. PubMed ID: 32116063
    [No Abstract]   [Full Text] [Related]  

  • 7. Dementia Therapy Targeting Tau.
    Buee L
    Adv Exp Med Biol; 2019; 1184():407-416. PubMed ID: 32096053
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Sources of extracellular tau and its signaling.
    Avila J; Simón D; Díaz-Hernández M; Pintor J; Hernández F
    J Alzheimers Dis; 2014; 40 Suppl 1():S7-S15. PubMed ID: 24531154
    [TBL] [Abstract][Full Text] [Related]  

  • 9. What is the pathological significance of tau oligomers?
    Cowan CM; Quraishe S; Mudher A
    Biochem Soc Trans; 2012 Aug; 40(4):693-7. PubMed ID: 22817718
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Microtubule-associated protein tau as a therapeutic target in Alzheimer's disease.
    Iqbal K; Gong CX; Liu F
    Expert Opin Ther Targets; 2014 Mar; 18(3):307-18. PubMed ID: 24387228
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Further understanding of tau phosphorylation: implications for therapy.
    Medina M; Avila J
    Expert Rev Neurother; 2015 Jan; 15(1):115-22. PubMed ID: 25555397
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Phosphorylated tau targeted small-molecule PROTACs for the treatment of Alzheimer's disease and tauopathies.
    Jangampalli Adi P; Reddy PH
    Biochim Biophys Acta Mol Basis Dis; 2021 Aug; 1867(8):166162. PubMed ID: 33940164
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Phosphorylated mitogen-activated protein kinase (MAPK/ERK-P), protein kinase of 38 kDa (p38-P), stress-activated protein kinase (SAPK/JNK-P), and calcium/calmodulin-dependent kinase II (CaM kinase II) are differentially expressed in tau deposits in neurons and glial cells in tauopathies.
    Ferrer I; Blanco R; Carmona M; Puig B
    J Neural Transm (Vienna); 2001; 108(12):1397-415. PubMed ID: 11810404
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Increase in tau tyrosine phosphorylation correlates with the formation of tau aggregates.
    Vega IE; Cui L; Propst JA; Hutton ML; Lee G; Yen SH
    Brain Res Mol Brain Res; 2005 Aug; 138(2):135-44. PubMed ID: 15913839
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Targeting the ensemble of heterogeneous tau oligomers in cells: A novel small molecule screening platform for tauopathies.
    Lo CH; Lim CK; Ding Z; Wickramasinghe SP; Braun AR; Ashe KH; Rhoades E; Thomas DD; Sachs JN
    Alzheimers Dement; 2019 Nov; 15(11):1489-1502. PubMed ID: 31653529
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Tau phosphorylation and aggregation in Alzheimer's disease pathology.
    Avila J
    FEBS Lett; 2006 May; 580(12):2922-7. PubMed ID: 16529745
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Twice is better: highlights of the second meeting focused on tau biology and pathology.
    Skoulakis EM; Mudher A
    Biochem Soc Trans; 2012 Aug; 40(4):641-3. PubMed ID: 22817708
    [TBL] [Abstract][Full Text] [Related]  

  • 18. O-GlcNAcase inhibitors as potential therapeutics for the treatment of Alzheimer's disease and related tauopathies: analysis of the patent literature.
    Bartolomé-Nebreda JM; Trabanco AA; Velter AI; Buijnsters P
    Expert Opin Ther Pat; 2021 Dec; 31(12):1117-1154. PubMed ID: 34176417
    [No Abstract]   [Full Text] [Related]  

  • 19. Tauopathies and tau oligomers.
    Takashima A
    J Alzheimers Dis; 2013; 37(3):565-8. PubMed ID: 23948895
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Expression of a truncated tau protein induces oxidative stress in a rodent model of tauopathy.
    Cente M; Filipcik P; Pevalova M; Novak M
    Eur J Neurosci; 2006 Aug; 24(4):1085-90. PubMed ID: 16930434
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.